Using ex vivo avatars to understand immune reactivation in cancer
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Ongoing research will help to clarify how CHIP clones may be used to guide therapy for patients with solid tumours
Which immune cell type is it best to target therapeutically in brain tumours?
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report